Marshall Wace, LLP Relmada Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 50,570 shares of RLMD stock, worth $152,721. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,570
Previous 156,619
67.71%
Holding current value
$152,721
Previous $469,000
65.25%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RLMD
# of Institutions
81Shares Held
12.3MCall Options Held
229KPut Options Held
138K-
Franklin Resources Inc San Mateo, CA1.3MShares$3.93 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.8 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$3.58 Million0.01% of portfolio
-
Parsons Capital Management Inc1MShares$3.03 Million0.21% of portfolio
-
Palo Alto Investors LP Palo Alto, CA732KShares$2.21 Million0.33% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $86.4M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...